10/31/2014 9:41 AM IPN.PA 39.86 € (-0.03 %) Data: Yahoo Finance
Startsidan

Press Releases

  • 10/29/2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014

    Ipsen: sales in the 3rd quarter and first nine months of 2014
  • 10/22/2014

    Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

    Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate
  • 10/10/2014

    Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients

    Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients
  • 10/10/2014

    Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer

    Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer
  • 10/2/2014

    Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities

    Susheel Surpal steps down as Executive Vice President, Chief Financial Officer of Ipsen to pursue other opportunities
  • 9/27/2014

    Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress

    Ipsen presents preliminary results of exploratory proof-of-concept study with tasquinimod in four advanced tumor types at the ESMO 2014 Congress
  • 9/1/2014

    Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe

    Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review and in Europe
  • 8/29/2014

    Ipsen: 2014 half-year results and 2014 objectives

    Ipsen: 2014 half-year results and 2014 objectives
  • 8/27/2014

    Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014

    Ipsen North America Announces Second Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2014
  • 7/17/2014

    New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

    New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors